Administration of adenovirus encoding anti-CD20 antibody gene induces B-cell deletion and alleviates lupus in the BWF1 mouse model.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  International Immunopharmacology

• Publication date

  2011-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.intimp.2011.01.014PMID 21272677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Costimulation Blockade in the Treatment of Rheumatic Diseases

  2012cited by this paper
• Monoclonal antibodies in the treatment of systemic lupus erythematosus.

  2009cited by this paper
• Use of rituximab in patients with systemic lupus erythematosus: an update.

  2009cited by this paper
• [Treatment of proliferative glomerulonephritis of systemic lupus erythematosus. Recent development and current recommendations].

  2008cited by this paper
• B-cell-directed therapies in systemic lupus erythematosus.

  2008cited by this paper
• Traitement des glomrulonphrites lupiques prolifratives. volution des ides et situation en 2008

  2008cited by this paper
• Anti-Sm B cell tolerance and tolerance loss in systemic lupus erythematosus

  2008cited by this paper
• Hormonal regulation of B-cell function and systemic lupus erythematosus

  2008cited by this paper
• Severe gastrointestinal involvement in systemic lupus erythematosus treated with rituximab and cyclophosphamide (B-cell depletion therapy).

  2007cited by this paper
• Peptide-based therapy in lupus: promising data.

  2007cited by this paper
• B cells in SLE: different biological drugs for different pathogenic mechanisms.

  2007cited by this paper
• B cell biology and dysfunction in SLE.

  2007cited by this paper
• Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

  2007cited by this paper
• B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus

  2006cited by this paper
• Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20).

  2006cited by this paper
• Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease.

  2006cited by this paper
• Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate.

  2005cited by this paper
• SLE: challenges and candidates in human disease.

  2005cited by this paper
• Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases)

  2005cited by this paper
• Stable antibody expression at therapeutic levels using the 2A peptide

  2005cited by this paper
• SLE: translating lessons from model systems to human disease.

  2005cited by this paper
• T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.

  2005cited by this paper
• Adenovirus vectors: biology, design, and production.

  2004cited by this paper
• Adenoviral vectors for gene transfer and therapy

  2004cited by this paper
• Mouse CD20 expression and function.

  2004cited by this paper
• Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector.

  2003cited by this paper
• Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

  2003cited by this paper
• Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy

  2003cited by this paper
• Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.

  2003cited by this paper
• An open study of B lymphocyte depletion in systemic lupus erythematosus.

  2002cited by this paper
• Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

  2001cited by this paper
• CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice.

  2000cited by this paper
• CD20: a gene in search of a function.

  2000cited by this paper
• Antiviral Activity of an Intracellularly Expressed Single-Chain Antibody Fragment Directed against the Murine Leukemia Virus Capsid Protein

  2000cited by this paper
• Blockade of CD28/CTLA4-B7 pathway prevented autoantibody-related diseases but not lung disease in MRL/lpr mice.

  1999cited by this paper
• Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.

  1998cited by this paper
• Genetically Engineered Antibodies in Gene Transfer and Gene Therapy

  1998cited by this paper
• IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

  1997cited by this paper
• In Vitro and In Vivo Secretion of Cloned Antibodies by Genetically Modified Myogenic Cells

  1997cited by this paper
• E3 transcription unit of adenovirus.

  1995cited by this paper
• CD20: a regulator of cell-cycle progression of B lymphocytes.

  1994cited by this paper

• The efficacy of novel B cell biologics as the future of SLE treatment: a review.

  2014cites this paper